Research theme for competitive and other funds (1)：
2016 - 2020 Clinical study of the relationship between toxicity induced by pazopanib and pharmacokinetics
Papers (67)：
Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-Ichi Fujita. Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer. Cancer chemotherapy and pharmacology. 2024
Yukitaka Shibata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Ken-Ichi Fujita. A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer. Cancer chemotherapy and pharmacology. 2023. 92. 6. 465-474
Ken-Ichi Fujita, Natsumi Matsumoto, Remi Murase, Kosuke Takeshima, Hiroo Ishida, Yutaro Kubota. Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer. Clinical and translational science. 2023. 16. 10. 1741-1747
Yuta Nio, Hiroo Ishida, Natsumi Matsumoto, Sojiro Kusumoto, Yutaro Kubota, Takuya Tsunoda, Yasutsuna Sasaki, Ken-Ichi Fujita. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. BMC pulmonary medicine. 2022. 22. 1. 454-454
Jun Arai, Yumi Otoyama, Ken-Ichi Fujita, Kaku Goto, Masayuki Tojo, Atsushi Katagiri, Hisako Nozawa, Yutaro Kubota, Takehiro Takahashi, Hiroo Ishida, et al. Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer. BMC cancer. 2022. 22. 1. 428-428
